Renal arteries denervation with second generation systems: a remedy for resistant hypertension?
| Autor: | Stefano de Angelis, Riccardo di Pietro, Angela Dei Giudici, Simone Calcagno, Giuseppe Biondi-Zoccai, Massimiliano Scappaticci, Armando Del Prete, Francesco Versaci, Sebastiano Sciarretta, Francesca Sbandi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Arterial hypertension
medicine.medical_specialty Radiofrequency ablation Resistant hypertension 030204 cardiovascular system & hematology Settore MED/06 law.invention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Randomized controlled trial law Internal medicine medicine.artery Medicine AcademicSubjects/MED00200 030212 general & internal medicine Renal artery Denervation business.industry Renal arteries Articles Clinical trial Blood pressure Sympathetic nervous system Cardiology Cardiology and Cardiovascular Medicine business |
| Zdroj: | European Heart Journal Supplements : Journal of the European Society of Cardiology |
| ISSN: | 1554-2815 1520-765X |
| DOI: | 10.1093/eurheartj/suaa158 |
| Popis: | Initial studies on renal denervation (RDN) for the treatment of non-controlled arterial hypertension (HTN) through radiofrequency ablation of renal arteries demonstrated that RDN is an effective therapeutic strategy to reduce arterial blood pressure (BP). Nonetheless, the first randomized study, SYMPLICITY-HTN-3, failed to demonstrate a clear benefit for RND over the control group. Technologic evolution, with the introduction of new second generation multi-electrode devices, allowed deep energy delivery along the full circumference of the vessel. Two recent randomized studies involving patients assuming (SPYRAL HTN-ON MED) or not (SPYRAL HTN-OFF MED) antihypertensive pharmacologic treatment, demonstrated the efficacy and safety of RDN using second generation systems for radiofrequency ablation. Another recent randomized study demonstrated that RDN with ultrasounds (RADIANCE-HTN SOLO) of the main renal arteries led to a significant BP reduction compared to the control group. These studies have once again raised the interest of the scientific community towards attempting to define the appropriate role of RDN in the treatment of hypertension. Nonetheless, larger and longer clinical trials will be necessary to draw further conclusions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|